11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (vol 389, pg 1195, 2017)

Cameron D.; Piccart-Gebhart M. J.; Gelber R. D.

首页> 外文期刊>The Lancet >11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (vol 389, pg 1195, 2017)

【24h】

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (vol 389, pg 1195, 2017)

机译：11年后曲妥珠单抗后续辅助化疗在HER2阳性早期乳腺癌中：赫赛汀佐剂（HERA）试验的最终分析（Vol 389，PG 1195,2017）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2019年第10176期|共1页
作者
Cameron D.; Piccart-Gebhart M. J.; Gelber R. D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (vol 389, pg 1195, 2017) [J] . Cameron D., Piccart-Gebhart M. J., Gelber R. D. The Lancet . 2019,第10176期

机译：11年后曲妥珠单抗后续辅助化疗在HER2阳性早期乳腺癌中：赫赛汀佐剂（HERA）试验的最终分析（Vol 389，PG 1195,2017）
2. PS4 Best of ECCO 13 Herceptin (H) after adjuvant chemotherapy significantly improves disease-free survival (DFS) in HER2-positive early breast cancer (BC): HERA trial interim analysis [J] . European Journal of Cancer Supplements . 2005,第4期

机译：HER2阳性早期乳腺癌（BC）辅助化疗后的PS4 Best ECCO 13 Herceptin（H）显着改善无病生存期（DFS）：HERA试验中期分析
3. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：临时整体生存分析奥海蒂（BIG 4-11）：随机多中心，双盲，安慰剂对照试验比较化疗加上曲妥珠单抗Plusutuzumab与化疗加上Rrastuzumab加安慰剂作为可操作Her2阳性早期乳腺癌患者的辅助治疗
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. The Effects of Adjuvant Chemotherapy on Brain Function in Breast Cancer Patients and a Cancer-Chemotherapy Rodent Model. [D] . Barr, Alicia Thomas. 2014

机译：辅助化疗对乳腺癌患者脑功能的影响和癌症化学疗法的啮齿动物模型。
6. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [O] . David Cameron, Martine J Piccart-Gebhart, Richard D Gelber, -1

机译：HER2阳性早期乳腺癌辅助化疗后曲妥珠单抗治疗11年的随访：HERceptin佐剂（HERA）试验的最终分析
7. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [O] . Cameron, David A, Gianni, Luca, Baselga, José, 2017

机译：HER2阳性早期乳腺癌辅助化疗后曲妥珠单抗的11年随访：HERceptin佐剂（HERA）试验的最终分析

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (vol 389, pg 1195, 2017)

著录项

相似文献

相关主题

期刊订阅